ArticleTanaffos2014
Clinicopathologic and survival characteristics of malignant pleural mesothelioma registered in hospital cancer registry.
Article in Tanaffos, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The aftermath of asbestos prohibition in industry and its association with malignant mesothelioma in the south of Iran: An enduring predicament yet to be resolved.Health science reports · 2024Article
- Occupational respiratory disorders in Iran: a review of prevalence and inducers.Frontiers in medicine · 2024Review
- Synchronous Pleural and Peritoneal Mesothelioma: a Case Report and Narrative Review.Indian journal of surgical oncology · 2023Article
- Malignant pleural mesothelioma in a patient with pneumothorax: A cumbersome subtype both clinically and pathologically.Thoracic cancer · 2021Article
- An Overview of Asbestos and Malignant Pleural Mesothelioma: An Iranian PerspectiveAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of ResponseAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Recent Scientific Evidence Regarding Asbestos Use and Health Consequences of Asbestos Exposure.Current environmental health reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pleural mesothelioma (MPM) is a rare but fatal thoracic tumor, which in the majority of patients is caused by prolonged exposure to asbestos fibers. We aimed at presenting clinicopathological and treatment outcomes of 60 patients of MPM registered in our hospital cancer registry. MATERIALS AND
methodsDemographic characteristics of patients, exposure to asbestos, smoking habit, their clinicopathologic characteristics and survival analysis were described.
resultsSixty patients had MPM. Forty patients (66.7%) were men. The mean age of patients was 55.8±11 years. Chest pain and dyspnea were the most prevalent symptoms (31.7%, and 30%, respectively). Thirty-six (61.7%) patients reported asbestos exposure. The median survival and Progression free survival (PFS) were 10.5 months (0.95CI=9.22-11.78) and 7.57 months (0.95CI=5.68-9.45), respectively. In multivariate analysis, exposure to asbestos and epithelioid subtype significantly extended the survival time. Bilateral involvement, high blood level of LDH and platelet count ≥400,000 significantly shortened the overall survival.
conclusionMPM is still an important health problem in Iran. Given the aforementioned results, developing a national program to eliminate asbestos-related diseases according to the world health organization (WHO) recommendation is necessary.
Indexed as
Identifiers
25506370PMC4260067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.